[68Ga]Ga-FAPI-04与[18F]-FDG在胃癌原发及转移灶检测中的比较
该双中心回顾性研究纳入38例胃癌患者(31例腺癌、7例印戒细胞癌),比较[68Ga]Ga-FAPI-04与[18F]-FDG PET对原发灶和转移灶的检测效能。结果显示[68Ga]Ga-FAPI-04对原发胃癌的灵敏度为100%(38/38),显著高于[18F]-FDG的82%(31/38)(P=0.016)。
要点
- [68Ga]Ga-FAPI-04对原发胃癌灵敏度100%,[18F]-FDG为82%(P=0.016)。
- [18F]-FDG漏诊4例腺癌和3例印戒细胞癌。
- 肿瘤>4 cm者[68Ga]Ga-FAPI-04的SUVmax高于<4 cm者(11.0±4.5 vs 4.5±3.2,P=0.0015)。
核心结论
- 在该选定队列中,[68Ga]Ga-FAPI-04 PET对原发胃癌的检出率优于[18F]-FDG PET,可能在胃癌诊断和分期方面提供更好性能。
研究设计与样本
- 双中心回顾性分析,数据来自前瞻性母研究(临床试验HS-KY-2020-826和DF-2020-102)。
- 纳入38例胃癌患者(31例腺癌、7例印戒细胞癌),均行[68Ga]Ga-FAPI-04和[18F]-FDG PET/CT或PET/MR显像,由两名经验丰富的核医学医师判读并计算SUVmax,以活检或手术切除标本的组织病理学为最终诊断参考。
主要发现
- 原发胃癌检测灵敏度:[68Ga]Ga-FAPI-04为100%(38/38),[18F]-FDG为82%(31/38)(P=0.016)。
- [18F]-FDG PET漏诊4例腺癌和3例印戒细胞癌。
- 肿瘤>4 cm者[68Ga]Ga-FAPI-04平均SUVmax为11.0±4.5,高于<4 cm者的4.5±3.2(P=0.0015)。
- T2-4期肿瘤[68Ga]Ga-FAPI-04平均SUVmax为9.7±4.4,高于T1期的3.1±1.5(P=0.0002)。
- 在10例区域淋巴结转移和远处转移患者中,[68Ga]Ga-FAPI-04与[18F]-FDG的转移灶检测灵敏度分别为6/10和5/10。
关键数值与推荐
- 原发胃癌灵敏度:[68Ga]Ga-FAPI-04 100%(38/38)vs [18F]-FDG 82%(31/38),P=0.016。
- 肿瘤>4 cm vs <4 cm的[68Ga]Ga-FAPI-04平均SUVmax:11.0±4.5 vs 4.5±3.2,P=0.0015。
- T2-4期 vs T1期[68Ga]Ga-FAPI-04平均SUVmax:9.7±4.4 vs 3.1±1.5,P=0.0002。
- 转移灶检测灵敏度:[68Ga]Ga-FAPI-04 6/10 vs [18F]-FDG 5/10。
临床怎么用
- 对于原发胃癌特别是[18F]-FDG易漏诊的印戒细胞癌,可考虑使用[68Ga]Ga-FAPI-04 PET以提高检出率。
- 肿瘤较大(>4 cm)或T分期较晚(T2-4)者,[68Ga]Ga-FAPI-04摄取更高,可能更利于显示。
局限性
- 为回顾性分析且样本量有限(38例),结果需前瞻性临床试验验证。
- 转移灶检测仅基于10例患者,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The low sensitivity of [18F]-fluorodeoxyglucose ([18F]-FDG) for the diagnosis of gastric cancer limits its application. In this study, we aimed to investigate the potential advantage of [68 Ga]Ga-FAPI-04 over [18F]-FDG in the evaluation of gastric cancer. METHODS: This was a bicentric retrospective analysis of a prospective parent study (clinical trial: HS-KY-2020-826 (Huashan Hospital) and DF-2020-102 (Shanghai East Hospital)). Thirty-eight patients with gastric cancer (31 with adenocarcinoma and 7 with signet ring cell carcinoma) were included in this study. All of the participants underwent [68 Ga]Ga-FAPI-04 and [18F]-FDG imaging by positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance (MR). The scans were interpreted by two experienced nuclear medicine physicians, and the maximum standardized uptake value (SUVmax) was calculated. Histopathological findings obtained from biopsy or resected surgical specimens were used as a reference for the final diagnosis. RESULTS: For the detection of primary gastric cancer, the sensitivities of [68 Ga]Ga-FAPI-04 PET and [18F]-FDG PET were 100% (38/38) and 82% (31/38), respectively (P = 0.016). Four cases of adenocarcinoma and three cases of signet ring cell carcinoma were missed by [18F]-FDG PET. The mean SUVmax of [68 Ga]Ga-FAPI-04 in tumours greater than 4 cm (11.0 ± 4.5) was higher than that in tumours less than 4 cm (4.5 ± 3.2) (P = 0.0015). The mean SUVmax of [68 Ga]Ga-FAPI-04 was higher in T2-4 tumours (9.7 ± 4.4) than in T1 tumours (3.1 ± 1.5) (P = 0.0002). For the detection of metastatic lesions, the sensitivities of [68 Ga]Ga-FAPI-04 PET and [18F]-FDG PET in 10 patients with regional lymph node metastasis and distant metastasis were 6/10 and 5/10, respectively. CONCLUSION: In this selected cohort, [68 Ga]Ga-FAPI-04 PET had a superior detection rate than [18F]-FDG PET for primary gastric cancer. [68 Ga]Ga-FAPI-04 PET could provide better performance with regard to gastric cancer diagnosis and staging. Prospective clinical trials are warranted.
引用
- Jiang D, Chen X, You Z, et al. Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study. Eur J Nucl Med Mol Imaging. 2021. PMID: 34297193. doi:10.1007/s00259-021-05441-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。